Currently, there are 197.86M common shares owned by the public and among those 120.52M shares have been available to trade.
The company’s stock has a 5-day price change of 31.17% and -19.77% over the past three months. SANA shares are trading 68.14% year to date (YTD), with the 12-month market performance up to 18.69% higher. It has a 12-month low price of $2.74 and touched a high of $12.00 over the same period. SANA has an average intraday trading volume of 1.89 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 24.55%, -3.42%, and 9.11% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Sana Biotechnology Inc (NASDAQ: SANA) shares accounts for 50.28% of the company’s 197.86M shares outstanding.
It has a market capitalization of $1.52B and a beta (3y monthly) value of 1.48. The earnings-per-share (ttm) stands at -$1.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.84% over the week and 7.19% over the month.
Earnings per share for the fiscal year are expected to increase by 15.41%, and 5.40% over the next financial year.
Looking at the support for the SANA, a number of firms have released research notes about the stock. Rodman & Renshaw stated their Buy rating for the stock in a research note on June 26, 2024, with the firm’s price target at $16. H.C. Wainwright coverage for the Sana Biotechnology Inc (SANA) stock in a research note released on January 16, 2024 offered a Buy rating with a price target of $12. JMP Securities was of a view on September 25, 2023 that the stock is Mkt Outperform, while Citigroup gave the stock Buy rating on September 05, 2023, issuing a price target of $8. TD Cowen on their part issued Market Perform rating on August 14, 2023.
